BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 425-432

  Lohse, I ^a   Borgida, A ^b   Cao, P ^a   Cheung, M ^a   Pintilie, M ^a   Bianco, T ^b,c   Holter, S ^b   Ibrahimov, E ^a,b   Kumareswaran, R ^a   Bristow, R G ^a   Tsao, M S ^a,d,e   Gallinger, S ^b,c   Hedley, D W ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; DRUG RESISTANCE; DRUG SCREENING; GENETICS; GERMLINE MUTATION; MORTALITY; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938423352     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.220     Document Type: Article

References (29)

1. Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridöhl O, Ghadimi MB, Horstmann O, von Bernstorff W, Jochimsen L, Schmidt J, Eisold S, Estévéz-Schwarz L, Hahn SA, Schulmann K, Böck W, Gress TM, Zügel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A, Schmiegel W, Schäfer H, Rothmund M, Rieder H (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110(6): 902-906.
2. Chang Q, Juristica I, Do T, Hedley DW (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically-grown primary xenografts of human pancreatic cancer. Cancer Res 71(8): 3110-3120.
3. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM, Hruban RH (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16(2): 342-346.
4. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake 2nd DD, Lanchbury JS, Krivak TC (2012) BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 125(3): 677-682.
5. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S (1994) Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3(3): 209-212.
6. Foulkes WD, Shuen AY (2013) In brief: BRCA1 and BRCA2. J Pathol 230(4): 347-349.
7. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG (2011) MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 10(13): 2218-2232.
8. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C (1991) Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 10(3-4): 183-196.
9. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111(6): 1132-1138.
10. Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S (2015) Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148: 556-564.
11. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43): 5864-5874.
12. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44: 293-311.
13. Jones RM, Kotsantis P, Stewart GS, Groth P, Petermann E (2014) BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine. Mol Cancer Ther 13(10): 2412-2421.
14. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M (2001) Familial pancreatic cancer. Cancer J 7(4): 266-273.
15. Kobayashi H, Ohno S, Sasaki Y, Matsuura M (2013) Hereditary breast and ovarian cancer susceptibility genes. Oncol Rep 30(3): 1019-1029.
16. Koch CJ (2002) Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 352: 3-31.
17. Lohse I, Lourenco C, Ibrahimov E, Pintilie M, Tsao MS, Hedley DW (2014) Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts. Cancers 6: 459-471.
18. Lord EM, Harwell L, Koch CJ (1993) Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53: 5721-5726.
19. Lowery M, Shah MA, Smyth E, Epstein A, Segal A, Rosengarten O, Isacson R, Drukker L, Keinan A, Rachkiman M, Reissman P, Gabizon A, Kelsen D, O'Reilly EM (2011) A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. J Gastrointest Cancer 42(3): 160-164.
20. Muggia F, Safra T (2014) 'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res 34(2): 551-556.
21. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933): 1457-1461.
22. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11): 3-10.
23. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25(6): 735-747.
24. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159(1): 80-93.
25. Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A (2011) Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12(3): 165-168.
26. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Nat Cancer Inst 91: 1310-1316.
27. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11(20): 7508-7515.
28. Venkitaraman AR (2001) Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 114(Pt 20): 3591-3598.
29. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA. Australian Pancreatic Cancer Genome InitiativeGill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540): 495-501.